Open AccessP109: One‐Day Brentuximab‐Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
Author(s) -
Moatti Hannah,
Laroque MarieCéleste,
Renaud Loïc.,
Ravdan Odonchimeg,
SchmidtHieber Charlotte,
Madelaine Isabelle,
Di Blasi Roberta,
Thieblemont Catherine,
Brice Pauline
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000891004.90853.05
Subject(s) - bendamustine , medicine , brentuximab vedotin , surgery , refractory (planetary science) , salvage therapy , population , transplantation , lymphoma , oncology , chemotherapy , gastroenterology , hodgkin lymphoma , rituximab , biology , environmental health , astrobiology